<code id='336303EA38'></code><style id='336303EA38'></style>
    • <acronym id='336303EA38'></acronym>
      <center id='336303EA38'><center id='336303EA38'><tfoot id='336303EA38'></tfoot></center><abbr id='336303EA38'><dir id='336303EA38'><tfoot id='336303EA38'></tfoot><noframes id='336303EA38'>

    • <optgroup id='336303EA38'><strike id='336303EA38'><sup id='336303EA38'></sup></strike><code id='336303EA38'></code></optgroup>
        1. <b id='336303EA38'><label id='336303EA38'><select id='336303EA38'><dt id='336303EA38'><span id='336303EA38'></span></dt></select></label></b><u id='336303EA38'></u>
          <i id='336303EA38'><strike id='336303EA38'><tt id='336303EA38'><pre id='336303EA38'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:entertainment    Page View:74942
          Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

          Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

          The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

          advertisement

          But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          BD to buy Edwards patient monitoring unit for $4.2 billion
          BD to buy Edwards patient monitoring unit for $4.2 billion

          IanWaldie/GettyImagesBectonDickinsonplanstopay$4.2billionforEdwardsLifesciences’criticalcarebusiness

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

          LungcancerAdobeCHICAGO—DelfiDiagnostics,acompanyseekingtodevelopliquidbiopsyteststohelpscreenforlung